Roche announced that it will present more than 30 abstracts across over 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, taking place from October 17 to 21, 2025, in Berlin, Germany. The data highlight Roche’s commitment to delivering transformative therapies for some of the most challenging cancers, including breast, lung, gastrointestinal, and genitourinary cancers.
Key presentations include:
· Giredestrant: Primary results from the Phase III evERA Breast Cancer study, the first positive head-to-head Phase III trial investigating a selective estrogen receptor (ER) degrader-containing regimen versus standard of care in the post-cyclin-dependent kinase inhibitor setting for patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer. The study met both co-primary endpoints, showing a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations. Data will be presented as a late-breaking oral abstract.
· Tecentriq: Results from the IMvigor011 trial, the first global Phase III study using a circulating tumor DNA (ctDNA)-guided approach to post-surgery treatment in muscle-invasive bladder cancer (MIBC). Topline results show that patients with detectable ctDNA treated with Tecentriq® (atezolizumab) experienced statistically significant and clinically meaningful improvements in disease-free survival (DFS) and overall survival (OS). Data will be presented as part of the Presidential Symposium.
· Alecensa: Final overall survival (OS) data from the pivotal ALEX study of Alecensa® (alectinib), an established first-line treatment and standard of care for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). Data will be presented as a late-breaking oral abstract and published simultaneously in Annals of Oncology.
· Alecensa: Updated results from the Phase III ALINA study, reaffirming the role of adjuvant Alecensa as the standard of care for patients with resected ALK-positive NSCLC. After a median follow-up of approximately four years, Alecensa DFS data compared with chemotherapy will be presented.